Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VG712 vs Mogamulizumab in Relapsed or Refractory Mycosis Fungoides
NCT07529405Phase 2Not yet recruiting
- Sponsor
- Virogen Biotechnology
- Start
- Jul 2026
- Primary completion
- Dec 2030
- Modality
- Immunotoxins, Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of A-dmDT390-bisFv(UCHT1) in mycosis fungoides (MF), sponsored by Virogen Biotechnology. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
A-dmDT390-bisFv(UCHT1)
03
Conditions
mycosis fungoides (MF)
Beyond the preview
Go deeper on NCT07529405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07529405.